BiotechTube

Fosaprepitant

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chemotherapy-induced Nausea and Vomiting

Conditions

Chemotherapy-induced Nausea and Vomiting

Trial Timeline

Sep 1, 2013 → Dec 3, 2015

NCT ID
NCT01874119

About Fosaprepitant

Fosaprepitant is a phase 2 stage product being developed by Merck for Chemotherapy-induced Nausea and Vomiting. The current trial status is terminated. This product is registered under clinical trial identifier NCT01874119. Target conditions include Chemotherapy-induced Nausea and Vomiting.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01874119Phase 2Terminated

Competing Products

20 competing products in Chemotherapy-induced Nausea and Vomiting

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
36
GranisetronKyowa KirinPhase 3
77
ONO-7746Ono PharmaceuticalPhase 1
33
ONO-2910 + PlaceboOno PharmaceuticalPhase 2
52
PROCRIT 40,000 IU QW + PlaceboJohnson & JohnsonPhase 2
52
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 2
52
Hetrombopag + Hetrombopag plus Placebo + PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag + Matching placeboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
77
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue TherapyMerckPhase 3
77
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonistMerckPhase 3
77
Fosaprepitant + Dexamethasone + 5HT3MerckPhase 2
52
aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasoneMerckPhase 3
77
aprepitant + Comparator: ondansetron + Comparator: dexamethasone + Comparator: fosaprepitant dimeglumine + Comparator; Placebo (unspecified) + Comparator; Placebo (unspecified)MerckPhase 3
77
EMENDMerckPre-clinical
23
Fosaprepitant Dimeglumine + 5-HT3 antagonist + DexamethasoneMerckApproved
85
ondansetron clinical trial formulation + ondansetron marketed formulationMerckPhase 1
33
Aprepitant + Palonosetron + DexamethasoneMerckPhase 2
52
Fosaprepitant 150 mg + Aprepitant 165 mg + Aprepitant 250 mg + Dexamethasone (12-8-16-16 mg) + Dexamethasone (12-8-8-16 mg) + Ondansetron + MK0999MerckPhase 1
33

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85